VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E26.79 EPS (ttm)9.49 Insider Own0.20% Shs Outstand255.10M Perf Week8.15%
Market Cap63.46B Forward P/E16.67 EPS next Y15.25 Insider Trans-15.04% Shs Float254.81M Perf Month-11.74%
Income2.45B PEG2.46 EPS next Q3.58 Inst Own93.00% Short Float1.34% Perf Quarter9.92%
Sales7.95B P/S7.98 EPS this Y-12.50% Inst Trans1.03% Short Ratio2.06 Perf Half Y35.71%
Book/sh42.76 P/B5.94 EPS next Y7.24% ROA18.70% Target Price293.15 Perf Year17.48%
Cash/sh33.00 P/C7.70 EPS next 5Y10.90% ROE24.70% 52W Range176.36 - 292.75 Perf YTD15.74%
Dividend- P/FCF25.89 EPS past 5Y85.00% ROI22.50% 52W High-13.18% Beta0.59
Dividend %- Quick Ratio4.60 Sales past 5Y34.80% Gross Margin88.00% 52W Low44.12% ATR8.96
Employees3900 Current Ratio4.80 Sales Q/Q21.60% Oper. Margin36.90% RSI (14)47.03 Volatility3.38% 3.05%
OptionableYes Debt/Eq0.05 EPS Q/Q18.50% Profit Margin30.80% Rel Volume0.94 Prev Close246.72
ShortableYes LT Debt/Eq0.05 EarningsMay 05 AMC Payout0.00% Avg Volume1.65M Price254.17
Recom2.10 SMA20-3.62% SMA50-2.26% SMA20016.28% Volume1,558,246 Change3.02%
May-06-22Downgrade Robert W. Baird Outperform → Neutral $250
May-03-22Upgrade Morgan Stanley Underweight → Equal-Weight $250
Feb-03-22Downgrade RBC Capital Mkts Outperform → Sector Perform $269
Jan-27-22Reiterated Wolfe Research Outperform $271 → $282
Jan-27-22Reiterated Stifel Hold $213 → $222
Jan-27-22Reiterated RBC Capital Mkts Outperform $268 → $269
Jan-27-22Reiterated Morgan Stanley Underweight $203 → $208
Jan-27-22Reiterated JP Morgan Overweight $260 → $288
Jan-20-22Upgrade BMO Capital Markets Market Perform → Outperform $202 → $274
Dec-09-21Initiated Wells Fargo Overweight $270
Nov-19-21Initiated BMO Capital Markets Market Perform $202
Nov-19-21Downgrade Piper Sandler Overweight → Neutral $323 → $218
Sep-09-21Downgrade Stifel Buy → Hold $244 → $213
Sep-07-21Downgrade Morgan Stanley Equal-Weight → Underweight $202
Jul-20-21Downgrade SVB Leerink Mkt Perform → Underperform $170
Jul-19-21Resumed Wolfe Research Outperform $252
Jul-01-21Initiated Raymond James Mkt Perform
Jun-11-21Downgrade Daiwa Securities Outperform → Neutral $210
Feb-23-21Upgrade Robert W. Baird Neutral → Outperform $220 → $252
Feb-02-21Reiterated H.C. Wainwright Buy $315 → $275
May-16-22 02:23PM  
May-14-22 06:30AM  
May-12-22 09:11AM  
May-10-22 02:36PM  
May-09-22 11:05AM  
06:00AM  
05:54AM  
May-06-22 03:20PM  
01:23PM  
12:43PM  
12:11PM  
11:37AM  
11:02AM  
10:56AM  
10:37AM  
09:55AM  
09:40AM  
08:22AM  
07:00AM  
02:03AM  
May-05-22 05:15PM  
05:06PM  
04:01PM  
11:14AM  
05:52AM  
May-04-22 03:19PM  
02:21PM  
01:39PM  
01:22PM  
11:39AM  
11:07AM  
08:42AM  
07:02AM  
06:00AM  
May-03-22 01:00PM  
11:53AM  
10:55AM  
10:47AM  
06:37AM  
06:35AM  
May-02-22 04:32PM  
03:58PM  
03:21PM  
01:38PM  
01:34PM  
01:11PM  
11:49AM  
11:10AM  
11:04AM  
10:44AM  
10:26AM  
10:10AM  
10:01AM  
08:30AM  
06:22AM  
06:02AM  
Apr-30-22 09:05AM  
Apr-29-22 03:12PM  
02:25PM  
12:29PM  
11:05AM  
07:43AM  
07:35AM  
Apr-28-22 03:02PM  
02:35PM  
11:12AM  
10:44AM  
Apr-27-22 05:50PM  
12:17PM  
11:49AM  
11:37AM  
11:01AM  
Apr-26-22 12:34PM  
11:48AM  
10:15AM  
09:46AM  
Apr-25-22 01:16PM  
11:46AM  
09:02AM  
Apr-22-22 02:58PM  
01:19PM  
11:36AM  
07:39AM  
Apr-21-22 05:50PM  
04:05PM  
09:58AM  
09:32AM  
Apr-20-22 07:04PM  
06:00PM  
05:45PM  
12:10PM  
11:14AM  
10:02AM  
08:35AM  
07:00AM  
06:55AM  
Apr-19-22 11:52AM  
09:23AM  
Apr-18-22 06:04AM  
Apr-16-22 06:18AM  
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; Mammoth Biosciences; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanna BastianoEVP, Cell & Genetic TherapiesMay 04Sale275.09369,90341,660May 06 04:05 PM
Arbuckle Stuart AEVP, COOMay 02Sale263.9830680,77864,760May 04 05:21 PM
Sanna BastianoEVP, Cell & Genetic TherapiesMay 02Sale259.1632082,93041,696May 04 05:10 PM
Bhatia Sangeeta N.DirectorMay 02Sale258.94737190,8425,903May 04 05:09 PM
WAGNER CHARLES F JREVP & Chief Financial OfficerMay 02Sale258.8334388,77842,730May 04 05:07 PM
Liu JoySVP, General CounselApr 29Sale275.4112033,04914,334May 03 04:28 PM
Ambrose KristenSVP & Chief Accounting OfficerApr 25Sale269.5532788,1433,496Apr 27 04:05 PM
Lee YuchunDirectorApr 18Option Exercise81.542,000163,0803,875Apr 20 04:05 PM
Lee YuchunDirectorApr 18Sale284.232,000568,4671,875Apr 20 04:05 PM
Lee YuchunDirectorApr 14Option Exercise81.542,000163,0803,875Apr 18 04:05 PM
Lee YuchunDirectorApr 14Sale289.062,000578,1171,875Apr 18 04:05 PM
Lee YuchunDirectorApr 13Option Exercise81.542,000163,0803,875Apr 14 04:35 PM
LEIDEN JEFFREY MExecutive ChairmanApr 13Sale289.0415,7894,563,65374,160Apr 14 04:35 PM
Lee YuchunDirectorApr 13Sale287.502,000575,0101,875Apr 14 04:35 PM
Lee YuchunDirectorApr 12Option Exercise81.542,000163,0803,875Apr 14 04:35 PM
Lee YuchunDirectorApr 12Sale281.032,000562,0511,875Apr 14 04:35 PM
Lee YuchunDirectorApr 11Option Exercise81.542,000163,0803,875Apr 12 04:07 PM
Lee YuchunDirectorApr 11Sale280.302,000560,5991,875Apr 12 04:07 PM
MCGLYNN MARGARET GDirectorApr 08Option Exercise127.545,000637,7006,099Apr 12 04:05 PM
Bhatia Sangeeta N.DirectorApr 08Option Exercise125.711,907239,7297,098Apr 12 04:05 PM
Lee YuchunDirectorApr 08Option Exercise81.542,000163,0803,875Apr 12 04:07 PM
Lee YuchunDirectorApr 08Sale278.572,000557,1411,875Apr 12 04:07 PM
Bhatia Sangeeta N.DirectorApr 08Sale280.201,907534,3415,191Apr 12 04:05 PM
MCGLYNN MARGARET GDirectorApr 08Sale280.225,0001,401,0801,099Apr 12 04:05 PM
Lee YuchunDirectorApr 07Option Exercise81.542,000163,0803,875Apr 08 05:57 PM
Sanna BastianoEVP, Cell & Genetic TherapiesApr 07Sale276.18561154,93542,782Apr 08 04:34 PM
Lee YuchunDirectorApr 07Sale274.862,000549,7201,875Apr 08 05:57 PM
Lee YuchunDirectorApr 06Option Exercise81.542,000163,0803,875Apr 08 05:57 PM
Lee YuchunDirectorApr 06Sale271.622,000543,2431,875Apr 08 05:57 PM
Lee YuchunDirectorApr 05Option Exercise81.542,000163,0803,875Apr 06 04:59 PM
Lee YuchunDirectorApr 05Sale272.502,000544,9931,875Apr 06 04:59 PM
Sanna BastianoEVP, Cell & Genetic TherapiesApr 05Sale275.233,163870,55243,343Apr 06 05:02 PM
Lee YuchunDirectorApr 04Option Exercise81.542,000163,0803,875Apr 06 04:59 PM
Sanna BastianoEVP, Cell & Genetic TherapiesApr 04Sale267.71562150,45246,506Apr 06 05:02 PM
Lee YuchunDirectorApr 04Sale267.722,000535,4311,875Apr 06 04:59 PM
WAGNER CHARLES F JREVP & Chief Financial OfficerApr 01Sale264.762,582683,60243,620Apr 05 04:06 PM
MCGLYNN MARGARET GDirectorMar 31Option Exercise127.545,000637,7006,099Apr 04 04:05 PM
MCGLYNN MARGARET GDirectorMar 31Sale262.275,0001,311,3461,099Apr 04 04:05 PM
Tatsis OuraniaEVP, Chief Reg. & Quality Off.Mar 17Sale250.112,833708,57247,356Mar 21 04:15 PM
WAGNER CHARLES F JREVP & Chief Financial OfficerMar 17Sale250.153,171793,21846,202Mar 21 04:12 PM
Sanna BastianoEVP, Cell & Genetic TherapiesMar 17Sale250.062,122530,62748,412Mar 21 04:10 PM
Tatsis OuraniaEVP, Chief Reg. & Quality Off.Feb 25Sale230.9532575,05850,189Feb 28 05:27 PM
Tatsis OuraniaEVP, Chief Reg. & Quality Off.Feb 18Sale231.00519119,88953,104Feb 22 05:03 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 18Sale230.974,312995,94949,687Feb 22 04:51 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 14Sale232.022,444567,05757,438Feb 16 04:05 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 11Sale235.022,297539,83759,882Feb 14 04:11 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 02Option Exercise86.524,660403,18370,357Feb 03 04:06 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 02Sale251.474,6601,171,84265,697Feb 03 04:06 PM
WAGNER CHARLES F JREVP & Chief Financial OfficerFeb 02Sale250.072,944736,20657,435Feb 03 04:29 PM
Sanna BastianoEVP, Cell & Genetic TherapiesFeb 02Sale250.981,040261,01754,952Feb 03 04:26 PM
MCGLYNN MARGARET GDirectorJan 28Option Exercise127.545,000637,7006,099Feb 01 04:09 PM
MCGLYNN MARGARET GDirectorJan 28Sale241.795,0001,208,9601,099Feb 01 04:09 PM
Sachdev AmitEVP, Chief Patient OfficerNov 15Sale187.19519,54731,928Nov 16 04:07 PM
Arbuckle Stuart AEVP, COONov 15Sale187.26356241,103Nov 16 04:05 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 15Sale187.22346,36533,589Nov 16 04:04 PM
Kewalramani ReshmaCEO & PresidentAug 19Buy195.6510,0001,956,49273,754Aug 23 08:30 AM
SACHS BRUCE IDirectorAug 02Buy197.9115,0002,968,65041,210Aug 04 04:05 PM
Bhatia Sangeeta N.DirectorJun 02Sale209.69559117,2165,191Jun 04 04:03 PM